Article Text


Clinical, electrophysiological and VEGF 2-year response after lenalidomide or stem cell transplantation in patients with POEMS syndrome
  1. Mariangela Bianco1,
  2. Fabrizia Terenghi1,
  3. Francesca Gallia1,
  4. Andrea Nozza2,
  5. Antonietta Scarale1,
  6. Mohammed Zhiad Fayoumi1,
  7. Claudia Giannotta1,
  8. Eduardo Nobile-Orazio1
  1. 1 Department of Medical Biotechnology and Translational Medicine, Milan University, Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center, Rozzano, Italy
  2. 2 Department of Medical Oncology and Haematology, Humanitas Clinical and Research Centre, Rozzano, Italy
  1. Correspondence to Professor Eduardo Nobile-Orazio, , Department of Medical Biotechnology and Translational Medicine, Milan University, Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center, Milan, MI 20089, Italy; eduardo.nobile{at}

Statistics from


POEMS syndrome is a rare multisystem disease characterised by polyneuropathy (P), organomegaly (O), endocrinopathy (E), monoclonal gammopathy (M) and skin changes (S).1 A usually severe demyelinating and axonal neuropathy is often the most prominent and disabling clinical manifestation.2 The pathogenesis of POEMS syndrome is unclear even if overproduction of vascular endothelial growth factor (VEGF) seems to play a major role.1 2 Autologous haematopoietic stem cell transplantation (HSCT) is now considered the most effective therapy in patients with disseminated disease.1 This therapy is however not feasible in all patients because of their advanced age or the presence of severe concomitant conditions. A number of immune or cytostatic agents have been also used with variable efficacy in POEMS syndrome,1 including lenalidomide whose efficacy we recently reported in 13 of the 18 treated patients.3 Little is known however on the degree of response to lenalidomide in comparison with HSCT.


We retrospectively reviewed the clinical, biological and electrophysiological data from 15 patients with POEMS syndrome diagnosed according the criteria proposed by Dispenzieri,1 who neurologically improved after therapy with lenalidomide or HSCT. All the patients had been treated and followed at our institution for at least 2 years. The study was approved by the institutional review board of our institute, and all the patients signed an informed consent for the review of their data.

Six patients (four males, two females; mean age at disease onset 48 years, range 41–53; mean disease duration 23 months, range 5–76) received high-dose melphalan chemotherapy followed by HSCT. Nine patients (seven males, two females; mean age at disease onset 54 years, range 44–65; mean disease duration 48 months, range 9–226) were treated with lenalidomide (25 mg/day for 21 days every month for 10–58 cycles) and oral dexamethasone (40 mg weekly).3 These patients did not undergo HSCT because of advanced age (2), severe concomitant conditions (3), patient preference (2) or relapse after a previous HSCT (2). Five patients treated with lenalidomide had not previously improved after therapy with intravenous immunoglobulins (IVIg) alone (1) or with corticosteroids (1) or cyclophosphamide (1), corticosteroids (1) or cyclophosphamide (1). Three patients treated with HSCT did not respond to previous therapy with IVIg (2) or local radiotherapy (1). In all the patients, the clinical, electrophysiological parameters and VEGF levels were assessed,3 before therapy (T0) and 1 (T1) and 2 years (T2) after starting the therapy. Clinical response was measured with the modified Medical Research Council (MRC) sumscore for muscle strength, range 0 (no contraction) to 80 (normal in 16 muscles), and the Overall Neuropathy Limitation Scale (ONLS), range 0 (normal) to 12 (unable to do any purposeful movement with arms and legs). Motor conduction studies were performed on the ulnar, tibial and peroneal nerves and included the measurement of distal and proximal compound motor action potential (CMAP) amplitudes, distal motor latency (DML) and motor nerve conduction velocity (MCV). Sensory conduction velocitie and sensory action potential were measured in the ulnar and sural nerves. VEGF levels were measured by ELISA (normal: <1000 pmol/L).3 In each group, the difference in the clinical, electrophysiological and biological parameters between baseline (T0) and 1 (T1) and 2 years (T2) after therapy was assessed by analysis of variance. A probability (p) value of <0.05 was considered statistically significant.


We found a significant improvement in the MRC sumscore and in the ONLS score after 1 and 2 years both in patients treated with HSCT (p=0.001) and in patients treated with lenalidomide (p=0.002) (table 1). The number of patients was too small for a statistical comparison of the improvement between the two groups, but the mean improvement was similar in the two groups.

Table 1

Clinical and electrophysiological findings in patients with POEMS syndrome treated with HSCT and lenalidomide

The frequency of nerves with no  potential before therapy was higher in lower than in upper limbs with no CMAP response in 67% peroneal nerves, 73% tibial nerves and 73% sural nerves before and, comparably, after treatment. Similarly infrequent was the response in the sensory ulnar nerve before therapy. We focused our study on the ulnar motor nerve. The mean DML of this nerve was reduced in patients treated with HSCT or lenalidomide, but the difference was significant only for HSCT (p=0.009; lenalidomide: p=0.08). MCV significantly improved in patients treated with HSCT (p=0.03) and lenalidomide (p=0.0004) as did distal CMAP amplitude (HSCT: p=0.009; lenalidomide: p=0.003). We did not compare the improvement between two groups, but the mean improvement was similar in the two groups (table 1).

Serum VEGF levels were reduced after treatment in patients treated with HSCT or lenalidomide, but the difference was significant for lenalidomide (T0 vs T1: p=0.027; T0 vs T2: p=0.046) but not for HSCT (T0 vs T1: p=0.156; T0 vs T2: p=0.112).


POEMS syndrome is a chronic progressive and often disabling disorder with estimated median survivals of nearly 14 years. In patients with disseminated disease, HSCT is considered the preferred treatment. Of the 59 patients receiving HSCT at the Mayo Clinic in Rochester, progression-free survival (PFS) after a median follow-up of 45 months was 98% and 75% after 1 year and 5 years, respectively.4 Lenalidomide has been recently reported to be effective in patients with POEMS syndrome and was not associated with neurotoxicity.3 5 A recent analysis of 51 patients with POEMS syndrome showed haematological response in 95% of the patients, a neurological response in 92% with a PFS at 1 year of 94%.5 In our study, HSCT and lenalidomide resulted in a significant improvement over 2 years in the MRC sumscore, ONLS score and in the ulnar CMAP and MCV, while serum VEGF levels were significantly reduced only in the lenalidomide group. Even if the number of treated patients was too small to compare statistically the difference in the improvement between the two groups, we observed a comparable degree of response in the two groups by the end of the first and second year. Since HSCT may not be suitable for all patients or may be refused by others for its potential risks, lenalidomide may represent a valuable alternative for at least 2 years in these patients or in those relapsing after HSCT.


We wish to thank Dr Emanuela Morenghi for statistical analysis. We also thank Celgene, Italy, for providing at no cost lenalidomide for patients originally enrolled in the open-label trial with lenalidomide and dexamethasone. The study was supported by a contribution from Humanitas Clinical and Research Center.


View Abstract


  • Contributors Study design: MB and EN-O. Experiments and procedures: FT, FG, AN, AS, MZF and CG. Data analysis and interpretation: MB and EN-O. Manuscript drafting: MB and EN-O. Manuscript editing: all authors. Approval of final draft: all authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer The company had no role in this study. 

  • Competing interests EN-O: personal fees for lecturing or advisory/scientific/safety board membership not related to this study from Baxter, Italy; CSL Behring, Switzerland; Kedrion Biopharma, Italy; LFB, France; Novartis, Switzerland; UCB, UK; Astellas Biopharma, the Netherlands. The other authors have no conflicts of interests.

  • Patient consent Not required.

  • Ethics approval Ethic Committee of Humanitas Clinical Institute.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.